We propose continuation of a multidisciplinary research training program in neuro-oncology based at the Massachusetts General Hospital Cancer Center. The primary objective of this two-year program is to train physician-scientists capable of providing a critical bridge between the biological sciences and experimental therapeutics. In order to achieve this objective the training program emphasizes a didactic curriculum in clinical research methodology as well as mentor-supervised clinical and basic science research experiences. All scholars are also assigned a clinical trial project during the course of the training program. All clinical and laboratory mentors participating in this training program have extensive experience in neuro-oncology research and training and provide an excellent resource for scholars interested in translational research. All scholars have access to senior biostatistical and computing support on all projects. An internal advisory committee chaired by the program director, as well as an external advisory committee, oversee the training program. In addition to clinical and basic science research facilities at the Massachusetts General Hospital, the Brigham and Women's Hospital, the Dana-Farber Cancer Institute and Harvard Medical School, the program includes investigators at the Children's Hospital, the Harvard School of Public Health and the Massachusetts Institute of Technology. There is no overlap between our unique grant focused on nervous system tumors and other training grants at Harvard focused on adult medical oncology. Candidates include physicians completing clinical training in adult and pediatric neuro-oncology, adult and pediatric neurosurgical oncology, adult and pediatric medical oncology and radiation oncology. A qualified pool of applicants from these disciplines can be expected to grow from existing and developing sources. Each trainee has a dedicated two-year block for research and training with minimal clinical responsibilities. Four postdoctoral positions are requested per year for five years with each scholar making a two-year commitment to investigation. Applicants will be selected through active recruitment by the program and individual faculty. We believe that the proposed training program capitalizes on a group of outstanding mentors and superb training facilities and will have the capability to produce productive patient-oriented researchers in neuro-oncology. Since the original award 10 years ago the quality of the program has steadily improved based upon such metrics as diversity in scholar clinical specialties, master degrees awarded, scholar publications, academic placement and scholar grant awards.
This grant is designed to train brain cancer specialists in the methods of research. The training program will expose the physician to coursework and hands-on experience in the laboratory. It is hoped that after their training these specialists will advance the field by developing clinical trials to test new treatments for brain cancer patients.
|Taylor, Jennie W; Dietrich, Jorg; Gerstner, Elizabeth R et al. (2015) Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol 121:557-63|
|Brastianos, Priscilla K; Taylor-Weiner, Amaro; Manley, Peter E et al. (2014) Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 46:161-5|
|Sullivan, James P; Nahed, Brian V; Madden, Marissa W et al. (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299-309|
|Sengupta, Soma; Weeraratne, Shyamal D; Cho, Yoon-Jae et al. (2014) Could ?5-GABA-A receptor activation be used as a target for managing medulloblastomas? CNS Oncol 3:245-7|
|Chudnovsky, Yakov; Kim, Dohoon; Zheng, Siyuan et al. (2014) ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state. Cell Rep 6:313-24|
|Palomero, Teresa; Couronné, Lucile; Khiabanian, Hossein et al. (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166-70|
|Snuderl, Matija; Batista, Ana; Kirkpatrick, Nathaniel D et al. (2013) Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152:1065-76|
|Goel, Shom; Gupta, Nisha; Walcott, Brian P et al. (2013) Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst 105:1188-201|
|Brastianos, Priscilla K; Horowitz, Peleg M; Santagata, Sandro et al. (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285-9|
|Quant, Eudocia C; Jeste, Shafali S; Muni, Rajeev H et al. (2009) The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ 339:b3354|
Showing the most recent 10 out of 12 publications